We analyzed 25 plasma samples from five healthy normal controls, five patients with LC, and five patients with early HCC (1 year before diagnosis, 6 months before diagnosis, and at diagnosis) using a 22 K protein chip to investigate the diagnostic potential of SF3B4 as a blood-based biomarker of HCC. Here, SF3B4 is linked to laryngotracheoesophageal cleft.